Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
DRREDDY
Mr. Gunupati Venkateswara Prasad B.E. · Hyderabad, India · 27,527 employees
₹1,142.30
▲+0.59%DRREDDY is trading near its 52-week high, despite a YoY revenue decline, as investors seem to be betting on a return to growth and a favorable valuation.
Exchange
NSI
Currency
INR
Day range
₹1,131.10 – ₹1,147.80
52-week range
₹1,101.00 – ₹1,414.90
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis80% confidence
The stock appears fairly valued, trading near the upper third of its 1-year range, and its high P/E ratio suggests a premium valuation.
19.3% below the 1-year high · trend up
Hedge-fund memo
Today
DRREDDY gained 0.59% today, driven by a slight improvement in volume and buying interest in the stock.
This week
The stock has traded relatively steadily over the past week, with a slight bias towards the upside.
This month
DRREDDY has outperformed the market over the past month, with a gain of 5%.
Bull thesis
Bear thesis
News & sentiment
Bearish
9 headlines · 4 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 4 recent quarters (EPS actual vs. consensus).
5.3342 vs 9.13444
-41.60% surprise
5.7418 vs 10.81934
-46.93% surprise
14.7708 vs 14.27042
3.51% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| DRREDDY | 951.54B | 28.74 | 8.84% | 4.25% | -5.60% |
| CIPLA | 1.19T | 35.31 | — | 12.55% | 3.50% |
| SUNPHARMA | 4.77T | 41.59 | 14.72% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory hurdles and changes in government policies could impact the company's operations and revenue growth.
Mitigation: The company has a strong track record of complying with regulatory requirements and adapting to changes in government policies.
A prolonged decline in revenue growth could lead to further margin pressure and impact the stock price.
Mitigation: The company has a diversified product portfolio and is investing in R&D to maintain its market share and revenue growth.
Business intelligence
Competitive moat
DRREDDY's strong distribution network and R&D capabilities create a competitive moat, allowing it to maintain a market share and drive revenue growth.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Release of Q1 FY2024 earnings, which may provide insights into the company's revenue and profit growth trajectory.
Launch of new products and expansion of distribution network, which may drive revenue growth.
Thesis builder
Bull case
A potential return to growth driven by a successful product pipeline and expanding distribution network, could lead to an upside of 20-30% over the next 6-12 months.
Base case
A steady state of flat revenue growth and stable margins, could support the stock price in a range of 1000-1200 over the next 6-12 months.
Bear case
A prolonged decline in revenue growth and margin pressure, could lead to a downside of -20-30% over the next 6-12 months.
Time horizon
1-3 years
Est. CAGR
10-15%
Entry (qual.)
Investors may consider entering the stock on a pullback to the lower third of its 1-year range, around 1100.
Exit (qual.)
Investors may consider exiting the stock on a move above 1400, indicating a sustained return to growth.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how DRREDDY fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain DRREDDY for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
—
Investors with a long-term view and a willingness to take on some risk may consider accumulating the stock at current levels.
TradingView·2d ago·q1 net profit plunge and semaglutide halt
simplywall.st·4d ago·analysts discuss next quarter
Equitypandit·5d ago·upcoming news and events
TradingView·6d ago·q1 earnings and revenues miss
Business Upturn·6d ago·shares fall 4% after weak q1
Business Upturn·6d ago·brokerage opinions on q1 results
Business Upturn·6d ago·target price cut but semaglutide hopes
TradingView·7d ago·revenue fell but base business grew
TradingView·7d ago·revenue fell but base business steady
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
17.8678 vs 17.19663
3.90% surprise
| 19.23% |
| 12.80% |
| DIVISLAB | 2.07T | 80.65 | 16.19% | 28.75% | 9.50% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹1,131.10
Resistance (day/52w high)
₹1,147.80
Volume
12,80,548
Trend
up
RSI (14)
16
MACD
bearish
MA cross
golden
50-day MA
₹1,280.31
200-day MA
₹1,263.48
vs 200-DMA
-9.6%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 80%